Cited by 399Cholangiocarcinoma and Gallbladder Cancer StudiesPediatric Hepatobiliary Diseases and TreatmentsGlioma Diagnosis and Treatment

The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.

Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas

Open access

Wang, P, Dong, Q, Zhang, C, Kuan, P-F, Liu, Y, Jeck, W R, Andersen, J B, Jiang, W, Savich, G L, Tan, T-X, Auman, J T, Hoskins, J M, Misher, A D, Moser, C D, Yourstone, S M, Kim, J W, Cibulskis, K, Getz, G, Hunt, H V, Thorgeirsson, S S, Roberts, L R, Ye, D, Guan, K-L, Xiong, Y, Qin, L-X, Chiang, D Y·2013·Oncogene

DOI 10.1038/onc.2012.315PMC PMC3500578

Open this paper in CoChat — free account

Abstract

Mutations in the genes encoding isocitrate dehydrogenase, IDH1 and IDH2, have been reported in gliomas, myeloid leukemias, chondrosarcomas and thyroid cancer. We discovered IDH1 and IDH2 mutations in 34 of 326 (10%) intrahepatic cholangiocarcinomas. Tumor with mutations in IDH1 or IDH2 had lower 5-hydroxymethylcytosine and higher 5-methylcytosine levels, as well as increased dimethylation of histone H3 lysine 79 (H3K79). Mutations in IDH1 or IDH2 were associated with longer overall survival (P=0.028) and were independently associated with a longer time to tumor recurrence after intrahepatic cholangiocarcinoma resection in multivariate analysis (P=0.021). IDH1 and IDH2 mutations were significantly associated with increased levels of p53 in intrahepatic cholangiocarcinomas, but no mutations in the p53 gene were found, suggesting that mutations in IDH1 and IDH2 may cause a stress that leads to p53 activation. We identified 2309 genes that were significantly hypermethylated in 19 cholangiocarcinomas with mutations in IDH1 or IDH2, compared with cholangiocarcinomas without these mutations. Hypermethylated CpG sites were significantly enriched in CpG shores and upstream of transcription start sites, suggesting a global regulation of transcriptional potential. Half of the hypermethylated genes overlapped with DNA hypermethylation in IDH1-mutant gliobastomas, suggesting the existence of a common set of genes whose expression may be affected by mutations in IDH1 or IDH2 in different types of tumors.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/onc.2012.315

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
Self-citation
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
The Epigenomics of Cancer
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine
Ito, S., Shen, L., Dai, Q., Wu, S. C., Collins, L. B., Swenberg, J. A., He, C., & Zhang, Y. (2011) · Science · doi:10.1126/science.1210597 · Cited by 3,451
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
Self-citation
Tet-Mediated Formation of 5-Carboxylcytosine and Its Excision by TDG in Mammalian DNA
He, Y., Li, B.-Z., Li, Z., Liu, P., Wang, Y., Tang, Q., Ding, J., Jia, Y., Chen, Z., Li, L., et al. (2011) · Science · doi:10.1126/science.1210944 · Cited by 2,776

Flagged first, then by citations

Show all 48 references

1 of the 48 references couldn’t be matched to a known paper.

Sorted by citations

Cholangiocarcinoma
Razumilava, N., & Gores, G. J. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61903-0 · Cited by 1,858
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
Bridgewater, J. A., Galle, P. R., Khan, S. A., Llovet, J. M., Park, J., Patel, T. C., Pawlik, T. M., & Gores, G. J. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.01.021 · Cited by 1,530
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
Bañales, J. M., Cardinale, V., Carpino, G., Marzioni, M., Andersen, J. B., Invernizzi, P., Lind, G. E., Folseraas, T., Forbes, S. J., Fouassier, L., et al. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.51 · Cited by 1,397
Self-citation
Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma
Ilyas, S. I., & Gores, G. J. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.10.013 · Cited by 1,331
Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis
Sia, D., Villanueva, A., Friedman, S. L., & Llovet, J. M. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.11.048 · Cited by 1,181
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Abou‐Alfa, G. K., Macarulla, T. M., Javle, M. M., Kelley, R. K., Lubner, S. J., Adeva, J., Cleary, J. M., Catenacci, D. V. T., Borad, M. J., Bridgewater, J. A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30157-1 · Cited by 1,159
Metabolic requirements for the maintenance of self-renewing stem cells
Ito, K., & Suda, T. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3772 · Cited by 1,014
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
Jusakul, A., Cutcutache, I., Yong, C. H., Lim, J. Q., Huang, M. N., Padmanabhan, N., Nellore, V., Kongpetch, S., Ng, A. W. T., Ng, L. M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0368 · Cited by 987
Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise
Saha, S. K., Zhu, A. X., Fuchs, C. S., & Brooks, G. A. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0446 · Cited by 787
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
Jiao, Y., Pawlik, T. M., Anders, R. A., Selaru, F. M., Streppel, M. M., Lucas, D. J., Niknafs, N., Guthrie, V. B., Maitra, A., Argani, P., et al. (2013) · Nature Genetics · doi:10.1038/ng.2813 · Cited by 689
Self-citation
New Horizons for Precision Medicine in Biliary Tract Cancers
Valle, J. W., Lamarca, Á., Goyal, L., Barriuso, J., & Zhu, A. X. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0245 · Cited by 632
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
Farshidfar, F., Zheng, S., Gingras, M., Newton, Y., Shih, J., Robertson, A. G., Hinoue, T., Hoadley, K. A., Gibb, E. A., Roszik, J., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.033 · Cited by 624
Self-citation
2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity
Sulkowski, P. L., Corso, C. D., Robinson, N. D., Scanlon, S. E., Purshouse, K. R., Bai, H., Liu, Y., Sundaram, R. K., Hegan, D. C., Fons, N. R., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal2463 · Cited by 575
Self-citation
Exome sequencing identifies distinct mutational patterns in liver fluke–related and non-infection-related bile duct cancers
Chan-on, W., Nairismägi, M., Ong, C. K., Lim, W. K., Dima, S., Pairojkul, C., Lim, K. H., McPherson, J. R., Cutcutache, I., Heng, H. L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2806 · Cited by 495
Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer
Saha, S. K., Parachoniak, C. A., Ghanta, K. S., Fitamant, J., Ross, K. N., Najem, M. S., Gurumurthy, S., Akbay, E. A., Sia, D., Cornellà, H., et al. (2014) · Nature · doi:10.1038/nature13441 · Cited by 460
IDH1andIDH2Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives
Yang, H., Ye, D., Guan, K., & Xiong, Y. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1773 · Cited by 477
Self-citation
Extreme vulnerability of IDH1 mutant cancers to NAD+ depletion
Tateishi, K., Wakimoto, H., Iafrate, A. J., Tanaka, S., Loebel, F., Lelic, N., Wiederschain, D., Bedel, O., Deng, G., Zhang, B., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.11.006 · Cited by 433
New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing
Ross, J. S., Wang, K., Gay, L. M., Al-Rohil, R. N., Rand, J. V., Jones, D., Lee, H. J., Sheehan, C. E., Otto, G. A., Palmer, G. A., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0352 · Cited by 453
Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities
Cairns, R. A., & Mak, T. W. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0083 · Cited by 452
Mutational landscape of intrahepatic cholangiocarcinoma
Zou, S., Li, J., Zhou, H., Frech, C., Jiang, X., Chu, J. S.-C., Zhao, X., Li, Y., Li, Q., Wang, H., et al. (2014) · Nature Communications · doi:10.1038/ncomms6696 · Cited by 437
Systemic therapies for intrahepatic cholangiocarcinoma
Kelley, R. K., Bridgewater, J. A., Gores, G. J., & Zhu, A. X. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.009 · Cited by 406
Coupling Krebs cycle metabolites to signalling in immunity and cancer
Ryan, D. G., Murphy, M. P., Frezza, C., Prag, H. A., Chouchani, E. T., O’Neill, L. A., & Mills, E. L. (2018) · Nature Metabolism · doi:10.1038/s42255-018-0014-7 · Cited by 398
The implications of IDH mutations for cancer development and therapy
Pirozzi, C. J., & Yan, H. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00521-0 · Cited by 417
Molecular targeted therapies: Ready for “prime time” in biliary tract cancer
Lamarca, Á., Barriuso, J., McNamara, M. G., & Valle, J. W. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.007 · Cited by 372
Anatomical, histomorphological and molecular classification of cholangiocarcinoma
Kendall, T. J., Verheij, J., Gaudio, E., Evert, M., Guido, M., Goeppert, B. F., & Carpino, G. (2019) · Liver International · doi:10.1111/liv.14093 · Cited by 367
EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma
Alvaro, D., Gores, G. J., Walicki, J., Hassan, C., Sapisochín, G., Komuta, M., Forner, A., Valle, J. W., Laghi, A., Ilyas, S. I., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.010 · Cited by 369
Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma
Borad, M. J., Champion, M. D., Egan, J. B., Liang, W. S., Fonseca, R., Bryce, A. H., McCullough, A. E., Barrett, M. T., Hunt, K. S., Patel, M. D., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004135 · Cited by 343
IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma
Kickingereder, P., Sahm, F., Radbruch, A., Wick, W., Heiland, S., von Deimling, A., Bendszus, M., & Wiestler, B. (2015) · Scientific Reports · doi:10.1038/srep16238 · Cited by 318
Functional and genetic deconstruction of the cellular origin in liver cancer
Marquardt, J. U., Andersen, J. B., & Thorgeirsson, S. S. (2015) · Nature reviews. Cancer · doi:10.1038/nrc4017 · Cited by 306
Self-citation
IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism
Grassian, A. R., Parker, S. J., Davidson, S. M., Divakaruni, A. S., Green, C. R., Zhang, X., Slocum, K. L., Pu, M., Lin, F., Vickers, C., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0772-t · Cited by 280
Resistance Mechanisms to Targeted Therapies in ROS1 + and ALK + Non–small Cell Lung Cancer
McCoach, C. E., Le, A. T., Gowan, K., Jones, K., Schubert, L., Doak, A. E., Estrada‐Bernal, A., Davies, K. D., Merrick, D. T., Bunn, P. A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2452 · Cited by 254
Metabolic rearrangements in primary liver cancers: cause and consequences
Satriano, L., Lewińska, M., Rodrigues, P. M., Bañales, J. M., & Andersen, J. B. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0217-8 · Cited by 245
Self-citation
Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates
Ye, D., Guan, K.-L., & Xiong, Y. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2017.12.005 · Cited by 242
Self-citation
Wild-type and mutated IDH1/2 enzymes and therapy responses
Molenaar, R. J., Maciejewski, J. P., Wilmink, J. W., & Noorden, C. J. F. V. (2018) · Oncogene · doi:10.1038/s41388-017-0077-z · Cited by 249
Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma
Moeini, A., Sia, D., Bardeesy, N. M., Mazzaferro, V., & Llovet, J. M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3296 · Cited by 246
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
Farshidfar, F., Zheng, S., Gingras, M., Newton, Y., Shih, J., Robertson, A. G., Hinoue, T., Hoadley, K. A., Gibb, E. A., Roszik, J., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.06.008 · Cited by 241
Self-citation
NADP+-IDH Mutations Promote Hypersuccinylation that Impairs Mitochondria Respiration and Induces Apoptosis Resistance
Li, F., He, X., Ye, D., Lin, Y., Yu, H., Yao, C., Huang, L., Zhang, J., Wang, F., Xu, S., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.017 · Cited by 244
Self-citation
The Spectrum of Achalasia: Lessons From Studies of Pathophysiology and High-Resolution Manometry
Kahrilas, P. J., & Boeckxstaens, G. E. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.038 · Cited by 236
Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study
Lowery, M. A., Burris, H. A., Jankú, F., Shroff, R. T., Cleary, J. M., Azad, N. S., Goyal, L., Maher, E. A., Gore, L., Hollebecque, A., et al. (2019) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(19)30189-x · Cited by 223
Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review
Boscoe, A. N., Rolland, C., & Kelley, R. K. (2019) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2019.03.10 · Cited by 210
Exploration of liver cancer genomes
Shibata, T., & Aburatani, H. (2014) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2014.6 · Cited by 202
CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice
Weber, J., Öllinger, R., Friedrich, M., Ehmer, U., Barenboim, M., Steiger, K., Heid, I., Mueller, S., Maresch, R., Engleitner, T., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1512392112 · Cited by 195
The CpG Island Methylator Phenotype: What's in a Name?
Hughes, L., Melotte, V., Schrijver, J. M. D., de Maat, M., Smit, V. T. H. B. M., Bovée, J. V. M. G., French, P. J., van den Brandt, P. A., Schouten, L. J., Meyer, T. D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4306 · Cited by 182
The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation
Molenaar, R. J., Radivoyevitch, T., Maciejewski, J. P., Noorden, C. J. F. V., & Bleeker, F. E. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.05.004 · Cited by 186
Emerging molecular therapeutic targets for cholangiocarcinoma
Ilyas, S. I., & Gores, G. J. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.026 · Cited by 180
Pan-cancer patterns of DNA methylation
Witte, T., Plass, C., & Gerhäuser, C. (2014) · Genome Medicine · doi:10.1186/s13073-014-0066-6 · Cited by 182
Metabolic reprogramming in cholangiocarcinoma
Raggi, C., Taddei, M. L., Rae, C. J., Braconi, C., & Marra, F. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.04.038 · Cited by 179
Challenges in the Treatment of Glioblastoma: Multisystem Mechanisms of Therapeutic Resistance
Noch, E., Ramakrishna, R. R., & Magge, R. (2018) · World Neurosurgery · doi:10.1016/j.wneu.2018.04.022 · Cited by 178
Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma
Boerner, T., Drill, E. N., Pak, L. M., Nguyen, B., Sigel, C., Doussot, A., Shin, P. J., Goldman, D. A., Gönen, M., Allen, P. J., et al. (2021) · Hepatology · doi:10.1002/hep.31829 · Cited by 170
Mutant IDH1 and thrombosis in gliomas
Unruh, D. J., Schwarze, S. R., Khoury, L., Thomas, C., Wu, M., Chen, L., Chen, R., Liu, Y., Schwartz, M. A., Amidei, C., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1620-7 · Cited by 173
Self-citation
Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2
Guilhamon, P., Eskandarpour, M., Halai, D., Wilson, G. A., Feber, A., Teschendorff, A. E., Gómez, V., Hergovich, A., Tirabosco, R., Amary, F. M., et al. (2013) · Nature Communications · doi:10.1038/ncomms3166 · Cited by 169
Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials
Lamarca, Á., Ross, P. J., Wasan, H. S., Hubner, R. A., McNamara, M. G., Lopes, A., Manoharan, P., Palmer, D., Bridgewater, J. A., & Valle, J. W. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz071 · Cited by 162
Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma
Saha, S. K., Gordan, J. D., Kleinstiver, B. P., Vu, P., Najem, M. S., Yeo, J.-C., Shi, L., Kato, Y., Levin, R. S., Webber, J. T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1442 · Cited by 160
5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft
Borodovsky, A., Salmasi, V., Turcan, Ş., Fabius, A. W. M., Baía, G. S., Eberhart, C. G., WEINGART, J. D., Gallia, G. L., Baylin, S. B., Chan, T. A.-T., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1408 · Cited by 158
Genomic Profiling of Intrahepatic Cholangiocarcinoma: Refining Prognosis and Identifying Therapeutic Targets
Zhu, A. X., Borger, D. R., Kim, Y., Cosgrove, D. C., Ejaz, A. M., Alexandrescu, S. T., Groeschl, R. T., Deshpande, V., Lindberg, J. M., Ferrone, C. R., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3828-x · Cited by 150
Radioprotection of IDH1 -Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198
Molenaar, R. J., Botman, D., Smits, M. A., Hira, V. V., van Lith, S. A., Stap, J., Henneman, P., Khurshed, M., Lenting, K., Mul, A. N., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3603 · Cited by 148
Oncometabolites: tailoring our genes
Nowicki, S., & Gottlieb, E. (2015) · FEBS Journal · doi:10.1111/febs.13295 · Cited by 148
Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma
Borger, D. R., Goyal, L., Yau, T., Poon, R. T., Ancukiewicz, M., Deshpande, V., Christiani, D. C., Liebman, H. M., Yang, H., Kim, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2649 · Cited by 138
Role of Hepatocyte Nuclear Factor 4α (HNF4α) in Cell Proliferation and Cancer
Walesky, C. M., & Apte, U. M. (2015) · Gene Expression · doi:10.3727/105221615x14181438356292 · Cited by 138
Lower Grade Gliomas
Youssef, G., & Miller, J. J. (2020) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-020-01040-8 · Cited by 144
Cancer metabolism and tumor microenvironment: fostering each other?
Yuan, Y., Li, H., Wang, P., Chen, L., Guo, D. S., Jiang, H., He, B., Qin, S., Wang, K., Li, N., et al. (2021) · Science China Life Sciences · doi:10.1007/s11427-021-1999-2 · Cited by 140
Self-citation
Dichotomy in intrahepatic cholangiocarcinomas based on histologic similarities to hilar cholangiocarcinomas
Akita, M., Fujikura, K., Ajiki, T., Fukumoto, T., Otani, K., Azuma, T., Itoh, T., Ku, Y., & Zen, Y. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.22 · Cited by 134
Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma
Goyal, L., Govindan, A., Sheth, R. A., Nardi, V., Blaszkowsky, L. S., Faris, J. E., Clark, J. W., Ryan, D. P., Kwak, E. L., Allen, J. N., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0210 · Cited by 134
Diagnostic and prognostic biomarkers in cholangiocarcinoma
Macı́as, R. I. R., Kornek, M., Rodrigues, P. M., Paiva, N. A., Castro, R. E., Urban, S. K., Pereira, S. P., Cadamuro, M., Rupp, C., Loosen, S. H., et al. (2019) · Liver International · doi:10.1111/liv.14090 · Cited by 134
Metabolic reprogramming and its clinical implication for liver cancer
Yang, F., Hilakivi-Clarke, L. A., Shaha, A., Wang, Y., Wang, X., Deng, Y., Lai, J., & Kang, N. (2023) · Hepatology · doi:10.1097/hep.0000000000000005 · Cited by 140
Cholangiocarcinoma: Molecular Pathways and Therapeutic Opportunities
Ilyas, S. I., Borad, M. J., Patel, T. C., & Gores, G. J. (2014) · Seminars in Liver Disease · doi:10.1055/s-0034-1394144 · Cited by 121
Cholangiocarcinoma
Squadroni, M., Tondulli, L., Gatta, G., Mosconi, S., Beretta, G. D., & Labianca, R. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.11.012 · Cited by 122
Isocitrate Dehydrogenase (IDH) Mutations Promote a Reversible ZEB1/MicroRNA (miR)-200-dependent Epithelial-Mesenchymal Transition (EMT)
Grassian, A. R., Lin, F., Barrett, R., Liu, Y., Jiang, W., Korpal, M., Astley, H. M., Gitterman, D. P., Henley, T., Howes, R., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.417832 · Cited by 122
Self-citation
Serum 2-Hydroxyglutarate Production in IDH1- and IDH2-Mutated De Novo Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group
Janin, M., Mylonas, E., Saada, V., Micol, J., Renneville, A., Quivoron, C., Koscielny, S., Scourzic, L., Forget, S., Pautas, C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.2047 · Cited by 131
Diverse modes of genomic alteration in hepatocellular carcinoma
Jhunjhunwala, S., Jiang, Z., Stawiski, E. W., Gnad, F., Liu, J., Mayba, O., Du, P., Diao, J., Johnson, S., Wong, K., et al. (2014) · Genome biology · doi:10.1186/s13059-014-0436-9 · Cited by 118
Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice
Jain, A., Kwong, L. N., & Javle, M. M. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0432-2 · Cited by 119
Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information
Ettrich, T. J., Schwerdel, D., Dolnik, A., Beuter, F., Blätte, T. J., Schmidt, S. A., Stanescu-Siegmund, N., Steinacker, J., Marienfeld, R. B., Kleger, A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-49860-0 · Cited by 120
Cholangiocarcinoma
Krasinskas, A. M. (2018) · Surgical pathology clinics · doi:10.1016/j.path.2018.02.005 · Cited by 119
Integrative Analysis Defines Distinct Prognostic Subgroups of Intrahepatic Cholangiocarcinoma
Goeppert, B. F., Tóth, R., Singer, S., Albrecht, T., Lipka, D. B., Lutsik, P., Brocks, D., Baehr, M., Muecke, O., Assenov, Y., et al. (2019) · Hepatology · doi:10.1002/hep.30493 · Cited by 112
Epigenetic therapy in gastrointestinal cancer: the right combination
Abdelfatah, E., Kerner, Z. J., Nanda, N., & Ahuja, N. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16644247 · Cited by 115
Intrahepatic cholangiocarcinoma: Molecular markers for diagnosis and prognosis
Rahnemai‐Azar, A. A., Weisbrod, A. B., Dillhoff, M. E., Schmidt, C. R., & Pawlik, T. M. (2017) · Surgical Oncology · doi:10.1016/j.suronc.2016.12.009 · Cited by 110
Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas
Wang, Y., Wild, A. T., Turcan, Ş., Wu, W., Sigel, C., Klimstra, D. S., Ma, X., Gong, Y., Holland, E. C., Huse, J. T., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz3221 · Cited by 109
The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets
Chong, D. Q., & Zhu, A. X. (2016) · Oncotarget · doi:10.18632/oncotarget.8775 · Cited by 109
Biliary tract cancers: current knowledge, clinical candidates and future challenges
Tariq, N.-U.-A., McNamara, M. G., & Valle, J. W. (2019) · Cancer Management and Research · doi:10.2147/cmar.s157092 · Cited by 111
The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma
Macı́as, R. I. R., Bañales, J. M., Sangro, B., Muntané, J., Avila, M. A., Lozano, E., Perugorria, M. J., Ruiz, F. J. P., Bujanda, L., & Marı́n, J. J. G. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.08.002 · Cited by 107
New Developments in the Pathogenesis and Therapeutic Targeting of the IDH1 Mutation in Glioma
Dimitrov, L., Hong, C. S., Yang, C., Zhuang, Z., & Heiss, J. D. (2015) · International Journal of Medical Sciences · doi:10.7150/ijms.11047 · Cited by 108
Intraductal tubulopapillary neoplasms of the bile ducts: clinicopathologic, immunohistochemical, and molecular analysis of 20 cases
Schlitter, A. M., Jang, K., Klöppel, G., Saka, B., Hong, S., Choi, H., Offerhaus, G. J. A., Hruban, R. H., Zen, Y., Konukiewitz, B., et al. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.61 · Cited by 103
Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines
Suijker, J., Oosting, J., Koornneef, A., Struys, E. A., Salomons, G. S., Schaap, F. G., Waaijer, C. J. F., Wijers‐Koster, P. M., Bruijn, I. H. B., Haazen, L. C. J. M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3723 · Cited by 106
The Ability to Diagnose Intrahepatic Cholangiocarcinoma Definitively Using Novel Branched DNA-Enhanced Albumin RNA In Situ Hybridization Technology
Ferrone, C. R., Ting, D. T., Shahid, M., Konstantinidis, I. T., Sabbatino, F., Goyal, L., Rice-Stitt, T. L., Mubeen, A., Arora, K. S., Bardeesey, N., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4247-8 · Cited by 101
The oncometabolite 2-hydroxyglutarate produced by mutant IDH1 sensitizes cells to ferroptosis
Wang, T., Liang, J.-Y., Zhang, C., Xiong, Y., Guan, K., & Yuan, H. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1984-4 · Cited by 106
Self-citation
Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients
Ruzzenente, A., Fassan, M., Conci, S., Simbolo, M., Lawlor, R. T., Pedrazzani, C., Capelli, P., D’Onofrio, M., Iacono, C., Scarpa, A., et al. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-5046-6 · Cited by 99
Genetics and Epigenetics of Glioblastoma: Applications and Overall Incidence of IDH1 Mutation
Liu, A., Hou, C., Chen, H., Zong, X., & Zong, P. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00016 · Cited by 105
Progress and prospects of biomarkers in primary liver cancer (Review).
Gao, Y.-X., Yang, T.-W., Yin, J., Yang, P.-X., Kou, B.-X., Chai, M., Liu, X.-N., & Chen, D. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5035 · Cited by 87
5-Hydroxymethylcytosine: An epigenetic mark frequently deregulated in cancer
Kroeze, L. I., van der Reijden, B. A., & Jansen, J. H. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.01.001 · Cited by 97
Evolution of the Experimental Models of Cholangiocarcinoma
Massa, A., Varamo, C., Vita, F., Tavolari, S., Neia, C. P., Brandi, G., Rizzo, A., Cavalloni, G., & Aglietta, M. (2020) · Cancers · doi:10.3390/cancers12082308 · Cited by 96
Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma
Ma, B., Meng, H., Tian, Y., Wang, Y., Song, T., Zhang, T., Wu, Q., Cui, Y., Li, H., Zhang, W., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06804-6 · Cited by 97
DNA Damage, DNA Repair and Cancer
Bernstein, C., Anil, R., Nfonsam, V. N., & Bernstei, H. (2013) · InTech eBooks · doi:10.5772/53919 · Cited by 115
Biochemical and Epigenetic Insights into L-2-Hydroxyglutarate, a Potential Therapeutic Target in Renal Cancer
Shelar, S. B., Shim, E., Brinkley, G. J., Kundu, A., Carobbio, F., Poston, T. L., Tan, J. C., Parekh, V., Benson, D. G., Crossman, D. K., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1727 · Cited by 89
A holistic view of cancer bioenergetics: mitochondrial function and respiration play fundamental roles in the development and progression of diverse tumors
Alam, M. M., Lal, S., FitzGerald, K. E., & Li, Z. (2016) · Clinical and Translational Medicine · doi:10.1186/s40169-016-0082-9 · Cited by 92
Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers
Unruh, D. J., Zewde, M. G., Buss, A., Drumm, M. R., Tran, A. N., Scholtens, D. M., & Horbinski, C. (2019) · Scientific Reports · doi:10.1038/s41598-019-45346-1 · Cited by 91
Animal models of cholangiocarcinoma
Loeuillard, E. J., Fischbach, S. R., Gores, G. J., & Ilyas, S. I. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.03.026 · Cited by 84
Digestive cancers: mechanisms, therapeutics and management
Zhan, T., Betge, J., Schulte, N., Dreikhausen, L., Hirth, M., Li, M., Weidner, P., Leipertz, A., Teufel, A., & Ebert, M. P. A. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02097-4 · Cited by 90
The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas
Wang, H., Tang, K., Liang, T., Zhang, W., Li, J.-Y., Wang, W., Hu, H., Li, M., Wang, H., He, X.-Z., et al. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0362-7 · Cited by 80
Self-citation
Metabolic Mechanisms of Epigenetic Regulation
Meier, J. L. (2013) · ACS Chemical Biology · doi:10.1021/cb400689r · Cited by 75
The Clinical Management of Cholangiocarcinoma in the United States and Europe: A Comprehensive and Evidence-Based Comparison of Guidelines
Fong, Z. V., Brownlee, S. A., Qadan, M., & Tanabe, K. K. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-09671-y · Cited by 72

Authors: Wang, P., Dong, Q., Zhang, C., Kuan, P.-F., Liu, Y., Jeck, W. R., Andersen, J. B., Jiang, W., Savich, G. L., Tan, T.-X., Auman, J. T., Hoskins, J. M., Misher, A. D., Moser, C. D., Yourstone, S. M., Kim, J. W., Cibulskis, K., Getz, G., Hunt, H. V., Thorgeirsson, S. S., Roberts, L. R., Ye, D., Guan, K.-L., Xiong, Y., Qin, L.-X., & Chiang, D. Y.
Affiliations: Fudan University (CN)
Shanghai Medical College of Fudan University (CN)
University of North Carolina at Chapel Hill (US)
National Institutes of Health (US)
Mayo Clinic (US)
Atrium Health Wake Forest Baptist (US)
Broad Institute (US)
Corresponding author: Xiong, Y
Qin, L-X
Chiang, D Y
ORCID: Wang, P
Dong, Q
Liu, Y
Jeck, W R
Andersen, J B
Auman, J T
Kim, J W
Cibulskis, K
Getz, G
Roberts, L R
Ye, D
Xiong, Y
Chiang, D Y
Venue: Oncogene
Publisher: Springer Science and Business Media LLC
Published: 2012-07-23
Volume: 32
Issue: 25
Pages: 3091-3100
ISSN: 0950-9232 (ISSN-L)
1476-5594
DOI: 10.1038/onc.2012.315
PMC: PMC3500578
OpenAlex: W2018041848
Cited by: 399
References: 48
Citations by year: 2026: 20 · 2025: 19 · 2024: 26 · 2023: 22 · 2022: 19 · 2021: 38 · 2020: 38 · 2019: 31 · 2018: 27 · 2017: 38 · 2016: 29 · 2015: 37 · 2014: 30 · 2013: 22 · 2012: 3
FWCI: 29.96
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Oncogene (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
UNC Libraries
Funders: Fudan University
National Institutes of Health (5r01ca149569-05)
National Human Genome Research Institute (R01HG006272)
National Cancer Institute (R01-CA149569, R01CA163834)
Topics: Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Keywords: IDH mutation, IDH1, IDH2, intrahepatic cholangiocarcinoma, DNA hypermethylation, 5-hydroxymethylcytosine, 5-methylcytosine, p53 activation, overall survival, tumor recurrence, glioblastoma, transcriptional regulation, tumor resection
MeSH terms: Base Sequence, Bile Duct Neoplasms, Bile Ducts, Intrahepatic, Brain Neoplasms, Glioblastoma, Histones, Humans, Isocitrate Dehydrogenase, Liver Neoplasms, Mutation, Neoplasm Recurrence, Local, Tumor Suppressor Protein p53, Sequence Analysis, DNA, Cholangiocarcinoma, CpG Islands, DNA Methylation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks